In this episode, hemophilia experts discuss how they integrate hemostatic rebalancing agents, including an antithrombin agent and tissue factor pathway inhibitors, into their practices for the care of patients with hemophilia. Listen for their insights on dosing, administration, and key differences between the rebalancing agents that inform their personalization of therapy.
In this podcast episode, experts Angela Weyand and Guy Young discuss their experience using hemostatic rebalancing agents for prophylaxis in patients diagnosed with hemophilia. Three rebalancing agents have now been approved, including concizumab, fitusiran, and marstacimab. These new rebalancing agents target the body's natural anticoagulants and provide individualized, convenient options for patients older than 12 years of age.This podcast explores similarities and differences between the rebalancing agents, such as dosing, necessary lab testing, and safety profiles, that are important to discuss with patients and their caregivers.
Presenters:
Angela Weyand, MD
Associate Professor, Pediatric Hematology Oncology
Co-Director, Combined Hematology/Gynecology Program
Pediatric Medical Director, Hemophilia Treatment Center
University of Michigan Medical School
Ann Arbor, Michigan
Guy Young, MD
Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disease Institute
Children's Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California
Get access to all of our new podcasts by subscribing to the CCO Neuroscience Podcast on Apple Podcasts, YouTube Podcasts, or Spotify.